A Study of DER 45-EV Gel to Treat Rosacea

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sol-Gel Technologies, Ltd.

Criteria

Inclusion Criteria:

• Males and females, 18 years of age or older

• Facial rosacea, with 12 or more inflammatory lesions (with no more than 2 nodules)

• Mild, Moderate or Severe (2, 3 or 4) rating of rosacea on the IGA

• Females of child-bearing potential must have negative urine pregnancy test result at baseline and must be willing to use an effective form of contraception throughout the study

Exclusion Criteria:

• Subjects who are pregnant, breast feeding, or planning a pregnancy during the study

• Allergy or sensitivity to ingredients in test product

• Any dermatological conditions of the face that may interfere with study evaluations

• Subjects unable to avoid or minimize exposure to factors that may exacerbate or trigger rosacea